S&CO Inc. Trims Stake in Insulet Co. (NASDAQ:PODD)

S&CO Inc. cut its position in Insulet Co. (NASDAQ:PODD) by 1.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,463 shares of the medical instruments supplier’s stock after selling 325 shares during the period. S&CO Inc.’s holdings in Insulet were worth $3,831,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. QRG Capital Management Inc. purchased a new stake in shares of Insulet in the third quarter worth $297,000. Diversified Trust Co lifted its position in Insulet by 90.9% during the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock valued at $1,842,000 after purchasing an additional 4,348 shares during the last quarter. Intech Investment Management LLC lifted its position in Insulet by 113.8% during the first quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock valued at $1,140,000 after purchasing an additional 3,539 shares during the last quarter. Natixis bought a new stake in shares of Insulet in the 1st quarter worth about $3,610,000. Finally, Seven Eight Capital LP bought a new stake in shares of Insulet in the 1st quarter worth about $1,418,000.

Insulet Price Performance

Insulet stock opened at $260.12 on Friday. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.40. The firm has a market capitalization of $18.24 billion, a price-to-earnings ratio of 44.54, a PEG ratio of 3.98 and a beta of 1.22. The company has a fifty day simple moving average of $237.77 and a 200-day simple moving average of $207.72. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Analyst Ratings Changes

Several research analysts recently commented on PODD shares. Sanford C. Bernstein started coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target on the stock. Piper Sandler raised their price target on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Morgan Stanley raised their target price on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. BTIG Research raised their target price on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Barclays raised their target price on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $253.27.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.